List of Multaq drug patents

Multaq is owned by Sanofi Aventis Us.

Multaq contains Dronedarone Hydrochloride.

Multaq has a total of 3 drug patents out of which 0 drug patents have expired.

Multaq was authorised for market use on 01 July, 2009.

Multaq is available in tablet;oral dosage forms.

Multaq can be used as reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals, reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals, management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.

The generics of Multaq are possible to be released after 30 June, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410167 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Apr, 2029

(6 years from now)

US9107900 SANOFI AVENTIS US Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality
Apr, 2029

(6 years from now)

US8602215 SANOFI AVENTIS US Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
Jun, 2031

(8 years from now)

Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient

Market Authorisation Date: 01 July, 2009

Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af

Dosage: TABLET;ORAL

How can I launch a generic of MULTAQ before it's patent expiration?
More Information on Dosage

MULTAQ family patents

19

United States

8

European Union

3

France

3

Taiwan, Province of China

2

Morocco

2

Korea, Republic of

2

Brazil

2

Australia

2

Chile

2

Dominican Republic

2

Uruguay

2

Mexico

2

Japan

2

IB

2

Ecuador

2

South Africa

2

Argentina

2

El Salvador

2

Colombia

2

Peru

2

EA

2

China

2

Canada

2

Costa Rica

2

Nicaragua

1

Malaysia

1

Ukraine

1

Tunisia

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in